Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another
A little over two years after pulling in its first Series A raise, autoimmune disease and cancer player Abcuro has some more cash to play with.
The Newton, MA-based biotech completed what it’s calling a Series A-1 fundraising round, netting $42 million to advance two antibodies that target KLRG1 in the hopes of modulating cytotoxic T and NK cells. Abcuro’s raise gives it a little over two years of runway, CEO David de Graaf told Endpoints News, and enough funding to run two clinical trials for a lead antibody and prepare its second antibody for IND studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.